

1 **Title:** Pulmonary Thromboembolism in Multidrug-Resistant Tuberculosis: A Case Series Highlighting the
2 Importance of Early Diagnosis and Management.

3
4 **Article type:** Case Report/Case Series

5
6 **Author names:**

- 7 1. Vikas Marwah
- 8 2. Gaurav Bhati
- 9 3. Robin Choudhary
- 10 4. Anmol Sharma

11
12 **Degrees and Affiliations:**

- 13 1. MD (Pulmonary Medicine), Senior Consultant, Dept of Pulmonary, Critical care and sleep medicine,
14 AICTS, Pune, India.
- 15 2. MD (Pulmonary Medicine), Senior resident, Dept of Pulmonary, Critical Care and Sleep Medicine,
16 AICTS, Pune, India.
- 17 3. MD (Pulmonary Medicine), Consultant, Dept of Pulmonary, Critical care and sleep medicine, Base
18 Hospital Delhi Cantt, New Delhi, India.
- 19 4. MBBS, Resident Internal Medicine, Base Hospital Delhi Cantt, India.

20
21 **ORCID (Open Researcher and Contributor Identifier):**

- 22 1. <https://orcid.org/0000-0002-7033-6090>
- 23 2. <https://orcid.org/0000-0002-5261-4675>
- 24 3. <https://orcid.org/0000-0002-9641-6849>
- 25 4. <https://orcid.org/0000-0003-1184-5298>

26
27 **About the author:** Dr. Anmol Sharma is currently pursuing his post-graduation in General medicine at Base
28 Hospital Delhi Cantt, New Delhi India as part of a 3-year program. He is the recipient of ICMR Studentship and
29 has won awards for best papers at various conferences.

30 **Corresponding author email:** robinch19@gmail.com.

31 **Acknowledgment:** Nil.

32 **Financing:** Nil

33 **Conflict of interest statement by authors:** Authors have nil to disclose.

34 **Compliance with ethical standards:** Informed consent of publication was obtained from the patient or a patient
35 representative.

36
37 **Authors Contribution Statement:**

38 1. Conceptualization: VM. Methodology: VM. Software: VM. Validation VM. Formal Analysis: VM. Writing
39 Review and Editing VM.

1 2. Conceptualization: GB Methodology: GB. Validation GB. Formal Analysis: GB. Data Curation: GB
2 Investigation: GB. Writing Review and Editing GB.

3 3. Methodology: RC. Software: RC. Validation RC. Formal Analysis: RC. Data Curation: RC Investigation: RC
4 Writing –Original Draft RC. Writing Review and Editing RC.

5 4. Methodology: AS. Software: AS. Validation AS. Formal Analysis: AS. Data Curation: AS Investigation: AS
6 Writing –Original Draft AS. Writing Review and Editing AS.

7
8 **Manuscript word count:** 1605.

9 **Abstract word count:** 171

10 **Number of Figures and Tables:** Figures – 3 Table -1

11
12 **Personal, Professional, and Institutional Social Network accounts.**

- 13 • **Facebook:** Nil
- 14 • **Twitter:** Nil
- 15 • **Instagram:** Nil
- 16 • **Linkedin:** Nil

17
18 **Discussion Points:** Tuberculosis (TB) is an infectious disease that can affect younger populations. It is a
19 hypercoagulable state that can lead to deep vein thrombosis but TB causing pulmonary embolism is a rare
20 phenomenon. Pulmonary embolism can be a fatal complication in TB and the treating physician should keep
21 this differential in mind while treating such cases.

22 **Dates**

23 Submission: 02/21/2023

24 Revisions: 06/12/2023, 08/06/2023

25 Responses: 06/28/2023, 08/30/2023

26 Acceptance: 09/11/2023

27 Publication: 10/26/2023

28
29 **Editors**

30 Associate Editor/Editor: Francisco J. Bonilla-Escobar

31 Student Editors: Joseph Tonge, Sebastian Diebel & Jonaviva Thomas

32 Copyeditor: Joseph Tonge

33 Proofreader:

34 Layout Editor:

35
36 **Publisher's Disclosure:** *This is a PDF file of an unedited manuscript that has been accepted for publication.*
37 *As a service to our readers and authors we are providing this early version of the manuscript. The manuscript*
38 *will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable*

1 *form. Please note that during the production process errors may be discovered which could affect the content,*
2 *and all legal disclaimers that apply to the journal pertain.*

3
4
5

Accepted, in-press

1 **ABSTRACT.**

2

3 Background-Pulmonary tuberculosis (PTB) is an established cause of arterial as well as venous thrombosis.
4 With the rising incidence of MDR tuberculosis, which has a prolonged treatment course, pulmonary
5 thromboembolism in such cases further complicates the treatment outcome in terms of mortality and morbidity.
6 TB causes systemic hypercoagulability, which may lead to both arterial and venous thrombosis. Therefore it is
7 important for treating physicians to be aware of the entity and have a sharp watch for the development of
8 Pulmonary thromboembolism in cases of MDR TB.

9 Case- We present the association of pulmonary thromboembolism (PTE) with MDR TB in three young males
10 who developed pulmonary thromboembolism during the treatment of MDR TB, along with their management
11 using anticoagulant agents.

12 Conclusion- PTE in cases of TB is rare but fatal. High suspicion of PTE in patients with MDR TB will help in
13 diagnosing the dreaded condition early and aid in reducing preventable mortality with PTE. Early recognition,
14 prompt diagnosis, and management is the key to saving the lives of those with this fatal complication.

15

16 **Key Words:** Pulmonary Thromboembolism, Multi-Drug Resistance, Tuberculosis, Case Report,
17 Hypercoagulability.

18

Accepted, in press

1 INTRODUCTION.

2
3 More than 25% of the global burden of tuberculosis is seen in developing countries like India with an estimated
4 27 lakh patients as per Global TB Report 2020¹. The incidence of multidrug-resistant tuberculosis/rifampicin-
5 resistant tuberculosis (MDR-TB/RR) is 11 per lakh of the Indian population and will keep on increasing in the
6 future. Tuberculosis (TB) is known to affect the coagulation parameters of the body². Identifying the patients
7 who are at high risk of developing venous thromboembolism and meticulous planning of their chemotherapy
8 consisting of anti-tuberculous medications and anticoagulants becomes of paramount importance to avoid
9 adverse outcomes. Patients with acute infections are 2-10 times more prone to develop venous
10 thromboembolism (VTE) as compared to the normal population³. VTE is also known to complicate chronic
11 infections like tuberculosis, affecting around 3-4 % of these patients and the estimated percentage can even be
12 higher since most cases are subclinical and are never diagnosed⁴. The study aimed to highlight the likely and
13 often missed complication of pulmonary thromboembolism in cases of tuberculosis and to prime the treating
14 physicians to be vigilant towards a differential of pulmonary thromboembolism while managing a case of TB.
15 We report three cases of MDR pulmonary tuberculosis manifesting with massive and sub-massive pulmonary
16 thromboembolism (PTE) with no prior apparent risk factors before illness. This study is important for physicians
17 managing MDR TB to be aware of PTE as a complication and take prompt action toward early diagnosis and
18 treatment of this potentially fatal clinical entity.

19 20 THE CASE

21 Case 1

22 A 21-year-old male, a nonsmoker reported complaints of breathlessness, fever, cough, right-sided pleuritic chest
23 pain, and loss of appetite of 10 days duration. His chest radiograph showed right-sided upper lobe consolidation
24 and pleural effusion, diagnostic pleurocentesis of which revealed exudative, lymphocyte-predominant fluid with
25 high Adenosine Deaminase (ADA). The patient was found to be sputum smear positive for acid-fast bacilli (AFB)
26 and cartridge-based nucleic acid amplification test (CBNAAT) was suggestive of rifampicin resistance. He was
27 started on anti-tubercular drugs, however, he started to have breathlessness on exertion. He underwent
28 computed tomography pulmonary angiography which revealed thrombo-embolism in the right pulmonary trunk
29 as shown in Figure 1. The patient was started on low molecular weight heparin at 60 mcg twice a day and later
30 switched to tab dabigatran 150 mg BD after 5 days along with second-line antituberculous therapy (ATT) to
31 which he showed a favorable response and gradually improved. Dabigatran was stopped after 6 months and a
32 thrombophilia workup was done which was negative.

33 Case 2

34 A 35-year-old healthy male presented with complaints of fever, dry cough, and progressive breathlessness
35 (MMRC II to III) along with a weight loss of two kilograms over two months. On evaluation, chest radiograph
36 and contrast-enhanced computed tomography of the chest were suggestive of right-sided pleural effusion as
37 shown in Figure 2. Pleural fluid analysis revealed lymphocyte-predominant, exudative effusion with ADA of 58
38 IU/ml. The patient was diagnosed with tuberculous pleural effusion and was started on first-line Anti-tubercular
39 therapy (ATT) comprising Tab Isoniazid 300mg Rifampicin 600 mg Pyrazinamide 1500 Ethambutol 1200 OD.
40 The patient had completed two months of antitubercular therapy when he suddenly had acute onset
41 breathlessness of one-day duration with hemodynamic collapse. The patient had sudden cardiac arrest and

1 Cardiopulmonary resuscitation (CPR) was started immediately. The patient was thrombolysed with 50 mg of
2 recombinant tissue plasminogen activator(r-TPA) and was intubated and placed on mechanical ventilation. He
3 improved clinically but developed acute kidney injury, hematuria, and upper gastrointestinal hemorrhage, which
4 was managed with pantoprazole infusion (80 mg stat followed by 8 mg/h infusion) along with hemodialysis, with
5 which the kidney function recovered. He was continued on Injection heparin 5000 U BD. Subsequently patient
6 was diagnosed to have loculated effusion on the right side of the chest and diagnostic pleurocentesis which
7 revealed exudative fluid with positive pleural fluid Mycobacterium tuberculosis (MTB) culture. A line probe assay
8 done on culture specimens showed resistance to rifampicin and isoniazid. Patient was diagnosed as multidrug-
9 resistant tuberculous pleural effusion and was treated with an MDR TB regimen (Tab Bedaquiline 400 mg QD
10 for 2 weeks followed by 200 mg thrice weekly, Tab Levofloxacin 750 mg OD, Tab Linezolid 600 mg OD,
11 Tab Clofazamine 100 mg OD, Tab Cycloserine 750 mg OD) and tab Apixaban 5 mg BD with which he
12 gradually improved. Thrombophilia work-up done after three months was negative.

13 Case 3

14 A 27-year-old male presented with complaints of cough, pleuritic chest pain, weight loss of four to five kilograms
15 over six months along with intermittent fever with evening fever of one-week duration. On evaluation, the patient
16 had bilateral pleural effusion on the chest radiograph. Computed tomography pulmonary angiography revealed
17 thromboembolism in the right main pulmonary trunk along with a few centrilobular nodules in the right upper
18 lobe and right lower lobe, bilateral pleural effusion, and a cold abscess over the right third rib as shown in Figure
19 3. The patient was diagnosed to have disseminated tuberculosis (pleuro-pulmonary and bone involvement),
20 CBNAAT of pus aspirate from cold abscess revealed MTB along with rifampicin resistance. The patient was
21 started on an MDR regimen along with oral Rivaroxaban 2.5 mg BD. Gradually patient improved and was
22 subsequently treated with rivaroxaban for six months and anti-tuberculous therapy was continued for 18 months.
23 Thrombophilia workup was done after rivaroxaban was stopped and it came back negative. We also did a color
24 doppler of the lower limb of all three patients which was normal.

25
26
27
28
29
30
31
32
33
34
35

DISCUSSION.

Venous thrombosis is frequently associated with recurrent thromboembolism which can also be fatal⁵. Tuberculosis can result in a transient hypercoagulable state with thrombocytosis, increased fibrinogen, factor VIII, plasminogen activator inhibitor 1 plasma levels; a decline in antithrombin III and protein C and S levels leading to activation of coagulation cascade and suppression of fibrinolytic pathway^{6,8}. The tubercle bacillus also promotes direct endothelial damage which aggravates the development of thrombus⁷. Production of pro-inflammatory cytokines (interleukin 1, interleukin 6, tumor necrosis factor α) in response to mycobacterial products also results in a hypercoagulable state^{9,10}. Lymphadenopathy seen frequently in these patients can also cause mechanical compression of adjacent blood vessels leading to stasis and finally thrombosis¹¹. Rifampin also has been implicated in the development of venous thrombosis and because of its enzyme-inducing effect, a higher dose of oral anticoagulants is frequently needed to achieve therapeutic INR levels¹². On review of Indian literature, we could identify various case reports of pulmonary TB along with documented deep venous thrombosis. whereas the association of TB along with PTE has been reported in fewer cases¹³⁻¹⁷. Mohan B, et al reported the largest case series from India with 5 cases of pulmonary embolism, in which all the five cases were males and with age less than 47 years. In our study, all the cases were young males out of which two cases had primary pleuro-pulmonary MDR tuberculosis while one had primary pulmonary MDR tuberculosis. Thrombolysis was warranted in only one of our patients as he developed hypoxia, hypotension, and cardiac arrest requiring mechanical ventilation while the other two cases were diagnosed based on out-of-proportion tachycardia and breathlessness on exertion and were managed with Low molecular weight heparin initially and oral anticoagulants later. In our study, two patients had breathlessness as the main presenting symptom with a relatively short duration of illness before reporting at a medical facility and their dyspnoea was disproportionate to the pulmonary lesions seen on the chest radiograph, along with a short history which raised the suspicion for pulmonary thromboembolism. These patients were all healthy young individuals with no prior risk factors for pulmonary thromboembolism apart from MDR tuberculosis¹⁴. Our study is the index case series from India of MDR TB cases complicated by PTE. It is also reiterated that our patients developed PTE despite there being no clinical or radiological evidence of DVT. In two of our cases, MDR TB was diagnosed on CBNAAT at presentation Thus, it is important to identify that MDR TB can be a risk factor for developing PTE and if there is a clinical suspicion of the same then these patients should be actively evaluated and they should be started on therapeutic anticoagulation till the diagnosis has been ruled out. PTE can be life-threatening so the index of suspicion should be high in these patients to prevent unnecessary mortality. The review of Indian literature of case reports and case series documenting PE with tuberculosis has been shown in Table 1. Case reports of pulmonary tuberculosis along with venous thromboembolism have been reported from India, among these very few had pulmonary thromboembolism. The association of pulmonary thromboembolism (PTE) with MDR TB has not been reported in India. We report three cases of this under-recognized association where timely diagnosis was life-saving. High suspicion of PTE in patients with MDR TB will help in diagnosing the dreaded condition early and aid in reducing preventable mortality.

1
2

Accepted, in-press

1 **SUMMARY - ACCELERATING TRANSLATION**

2

3 Title- Pulmonary Thromboembolism in Multidrug-Resistant Tuberculosis: A Case Series Highlighting the
4 Importance of Early Diagnosis and Management.

5 Main Problem to solve- Pulmonary Tuberculosis is a common disease worldwide and the cases of Multidrug
6 resistance are on the increasing trend. These patients are at a higher risk of developing pulmonary
7 thromboembolism which increases the mortality and morbidity in them.

8 The methodology aim of this retrospective observational study was to highlight this important entity for all the
9 clinicians treating such cases. In our study, these three cases of young males who were diagnosed with
10 Multidrug resistance Tuberculosis developed Pulmonary thromboembolism.

11 Results and conclusion were treated with MDR TB drugs and anticoagulation. Patients with MDR Tuberculosis
12 are predisposed to Pulmonary thromboembolism and its diagnosis requires a high index of suspicion and should
13 be promptly treated to reduce mortality.

14

Accepted, in-press

1 **REFERENCES.**

- 2
- 3 1. Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, Kapata N, Mfinanga S, Hasnain SE, Katoto PD, Bulabula AN. Global Tuberculosis Report 2020–Reflections on the Global TB burden, treatment and prevention efforts. *International journal of infectious diseases*. 2021 Dec 1;113:S7-12.
 - 4 2. Prasad R, Gupta N, Banka A. Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management. *Lung India*. 2018 Jan-Feb;35(1):78-81.
 - 5 3. Rogers MA, Levine DA, Blumberg N, Flanders SA, Chopra V, Langa KM. Triggers of hospitalization for venous thromboembolism. *Circulation*. 2012 May 1;125(17):2092-9.
 - 6 4. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals from the council on thrombosis (in consultation with the council on cardiovascular radiology), American Heart Association. *Circulation*. 1996 Jun 15;93(12):2212-45.
 - 7 5. Prandoni P, Bernardi E, Marchiori A, Lensing AW, Prins MH, Villalta S, Bagatella P, Sartor D, Piccioli A, Simioni P, Pagnan A. The long-term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. *Bmj*. 2004 Aug 26;329(7464):484-5.
 - 8 6. Robson SC, White NW, Aronson I, Woollgar R, Goodman H, Jacobs P. Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. *British journal of hematology*. 1996 Jun;93(4):943-9.
 - 9 7. Aguirre B, ME AS. Tuberculosis as a risk factor for venous thrombosis. In *Anales de medicina interna (Madrid, Spain: 1984)* 1993 Aug 1 (Vol. 10, No. 8, pp. 398-400).
 - 10 8. Ambrosetti M, Ferrarese M, Codecasa LR, Besozzi G, Sarassi A, Viggiani P, Migliori GB. Incidence of venous thromboembolism in tuberculosis patients. *Respiration*. 2006 May 1;73(3):396.
 - 11 9. Ogawa T, Uchida H, Kusumoto Y, Mori Y, Yamamura Y, Hamada S. Increase in tumor necrosis factor alpha-and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with *Mycobacterium tuberculosis*. *Infection and immunity*. 1991 Sep;59(9):3021-5.
 - 12 10. Gauldie J, Northemann W, Fey GH. IL-6 functions as an exocrine hormone in inflammation. Hepatocytes undergoing acute phase responses require exogenous IL-6. *Journal of Immunology (Baltimore, Md.: 1950)*. 1990 May 15;144(10):3804-8.
 - 13 11. Gogna A, Pradhan GR, Sinha RS, Gupta B. Tuberculosis presenting as deep vein thrombosis. *Postgrad Med J*. 1999 Feb;75(880):104-5.
 - 14 12. Kumar V, Gupta KB, Aggarwal R. Deep vein thrombosis in tuberculosis. *J Infect Dis Antimicrob Agents*. 2011;28:63–7.
 - 15 13. Naithani R, Agrawal N, Choudhary VP. Deep venous thrombosis associated with tuberculosis. *Blood Coagul Fibrinolysis*. 2007 Jun;18(4):377-80.
 - 16 14. Sharma RR, Acharya KV, Poornima V. A rare complication of pulmonary tuberculosis. *Journal, Indian Academy of Clinical Medicine*. 2007 Apr 1;8(2):179-181.
 - 17 15. Shah PA, Yaseen Y, Malik AH. Pulmonary Tuberculosis with Deep Venous Thrombosis. *WebmedCentral GENERAL MEDICINE* 2011;2(8): WMC002093.
 - 18 16. Mohan B, Kashyap A, Whig J, Mahajan V. Pulmonary embolism in cases of pulmonary tuberculosis: a unique entity. *Indian J Tuberc*. 2011 Apr;58(2):84-7.

- 1 17. Sangani J, Mukherjee S, Biswas S, Chaudhuri T, Ghosh G. Tuberculosis and acute deep vein
2 thrombosis in a pediatric case. Journal of Clinical and Diagnostic Research: JCDR. 2015
3 Jun;9(6):SD01.
- 4 18. Muley P, Shah U, Shah V, Gandhi D. Deep vein thrombosis with tuberculosis: A rare presentation of
5 common disease. Global J Med Public Health. 2014;3(1).

6
7
8
9


Accepted, in-press

1 **FIGURES AND TABLES.**

2

3

4 **Figure 1.** CT Pulmonary angiogram showing thrombo-embolism in the right pulmonary trunk.



5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1
2 **Figure 2.** CXR PA view showing Right-sided pleural effusion with a pigtail in situ.
3


4
5



6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

1
2
3
4
5
6

Figure 3 . Computed tomography pulmonary angiography revealed thromboembolism in the right main pulmonary trunk along with a few centrilobular nodules in the right upper lobe and right lower lobe and bilateral pleural effusion



7
8
9
10
11
12
13
14

1
2
3
4

Table 1. Indian Case Series And Case Reports Of Deep Vein Thrombosis Associated With Tuberculosis.

Author	Type of Study	Year	No of cases	Modality used for diagnosis	Treatment	Diagnosis VTE/PTE
Gogna A ¹¹	Case report	1999	2	Venous doppler, CECT abdomen	LMWH	VTE
Naithani R et al ¹³	Case report	2007	1	Venous Doppler	LMWH+ Warfarin	DVT
Sharma et al. ¹⁴	Case report	2007	1	Venous Doppler USG	Unfractionated heparin + warfarin	DVT
Kumar et al. ¹²	Case report	2011	1	Venous Doppler	Unfractionated heparin + warfarin	DVT
Shah et al. ¹⁵	Case report	2011	1	Venous Doppler	Enoxaparin + warfarin	DVT
Mohan B et al. ¹⁶	Case report	2011	5	Venous Doppler and CT	Streptokinase + urokinase +heparin	PTE
Muley et al. ¹⁸	Case report	2014	2	Venous Doppler USG	Unfractionated Heparin + warfarin	DVT
Sangani et al. ¹⁷	Case report	2015	1	Venous Doppler USG	Enoxaparin + warfarin	DVT

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

1 **Highlights-**

2

3 (a) Tuberculosis itself poses as a hypercoagulable state and poses a risk for deep vein thrombosis and venous
4 pulmonary thromboembolism.

5

6 (b) Physicians treating tuberculosis must be aware and alert regarding this uncommon yet fatal complication of
7 tuberculosis and have a keep clinical eye to diagnose thrombosis at earliest.

8

9 (c) Early diagnosis and management with anticoagulation and fibrinolysis when required is the key to limit the
10 mortality and morbidity associated with this disease.

Accepted, in-press